Doblin, Rick

founder and executive director of MAPS, the Multidisciplinary Association for Psychedelic Studies

Rick Doblin: Psychedelics

Lex Fridman Podcast · Jul 21, 2021

• Rick Doblin
• MAPS
• MDMA-assisted psychotherapy
• PTSD clinical trials
• FDA phase 3 trial design
• classic psychedelics versus MDMA
• MK-Ultra history
• Timothy Leary and Good Friday Experiment
• Ted Kaczynski and psychedelics
• drug policy reform
• psychedelic clinics and licensed legalization
• mystical experience and therapeutic outcome

Core ideas

Doblin defines "psychedelic" broadly (per its original coinage by Humphrey Osmond, meaning "mind manifesting") to include not just classic psychedelics (LSD, psilocybin, mescaline, ayahuasca, DMT) and MDMA (which he considers psychedelic-adjacent, an "empathogen" that increases self-acceptance and connection rather than dissolving the ego like classic psychedelics), but also non-drug altered states like dreams and holotropic breathwork. He frames psychedelics not as generating novel experiences but as revealing content — memories, emotions, and self-healing processes — that consciousness ordinarily filters out to conserve attention on immediate survival and social needs (citing Aldous Huxley's "reducing valve" concept), citing Sasha Shulgin's description of his first mescaline trip as "a human experience that the mescaline was helping him access" rather than "a mescaline experience." He is skeptical of Terence McKenna's account of contacting external "machine elves" during DMT trips, instead interpreting such entities as reflecting how much culture and preconception shape psychedelic content, and frames the deeper mystery as being about the scope of what's already "within" a person — including possible access to a Jungian collective unconscious, which he speculates may work through emotional resonance with culturally transmitted stories rather than literal information transfer.

Doblin recounts a personally significant 1970s DMT experience (with Terence McKenna and others present) in which he felt part of a vast evolutionary lineage, followed by the unsettling realization that if he is "part of everything," then any capacity — including Hitler's — is also latent within him; he treats this as an important, humbling insight about universal human potential rather than a nihilistic one, and connects it to a related ketamine experience in which he concluded there's no way to "get inside" a demagogue's head to change them from outside — reinforcing his belief that meaningful change requires mass psychological transformation ("mass mental health") rather than targeting a few powerful individuals. He stresses that context and psychological safety are essential to how psychedelic experiences unfold — citing examples ranging from prison inmates' inability to feel safe enough to close their eyes and breathe, to how the same underlying MK-Ultra-era LSD exposure produced radically different outcomes in different people (helping inspire Ken Kesey's novel One Flew Over the Cuckoo's Nest and the countercultural movement, while allegedly contributing to Ted Kaczynski's psychological unraveling) — concluding that the drug itself doesn't determine outcome, the interaction between drug, person, and context does.

He gives an extended account of MK-Ultra as a CIA program exploring psychedelics for interrogation, mind control, and "non-lethal incapacitance" (including secretly dosing unwitting subjects, such as through a San Francisco brothel under CIA surveillance), arguing it ironically backfired: intended to turn people inward and away from political engagement, it instead (via figures like Kesey, who became a bridge to the Grateful Dead and 1960s counterculture) helped catalyze exactly the anti-war, civil-rights, and environmental activism the CIA hoped to suppress — because genuine mystical/connective experiences tend to increase, not decrease, moral and political engagement. He similarly reframes the common narrative that 1960s psychedelic backlash was caused by "psychedelics going wrong" (people having bad, unprepared experiences), arguing the deeper cause was "psychedelics going right" — producing people less afraid of death and more willing to challenge the political and military status quo, which then triggered institutional suppression.

Doblin discusses his personal history with Timothy Leary (whom Nixon called "the most dangerous man in America"), describing Leary's early legitimate research (the Good Friday/Marsh Chapel experiment on religiously primed mystical experience, and the Concord Prison Experiment on reducing recidivism) alongside his later recklessness — exaggerating benefits and downplaying risks/data problems (including, Doblin says, fudged data in the Concord Prison study) as media attention grew, contrasted with Leary's genuine legacy of "think for yourself, question authority." Doblin describes his own 25-year and 34-year follow-up research on Good Friday and Concord Prison participants respectively, including uncovering a suppressed incident where a participant (having a genuine spiritual crisis) fled the ceremony and was tranquilized with Thorazine — a risk Leary's contemporaneous reporting omitted, exaggerating the study's clean success.

He details MAPS's origin as a nonprofit pharmaceutical company (not an academic research nonprofit) founded in 1986, a year after MDMA's 1985 criminalization — explicitly designed around drug development rather than knowledge-for-its-own-sake, pursuing a "mass mental health" mission via two tracks: clinical drug development and drug policy reform (so psychedelics could eventually be legally accessible for personal growth, not just clinical diagnoses). He explains MAPS's more recent creation of a wholly nonprofit-owned "public benefit corporation" (rather than a traditional for-profit pharma arm) to commercialize MDMA-assisted therapy while directing resulting profits back into the nonprofit's broader mission, contrasting this explicitly with a pure profit-maximization model (citing Johnson & Johnson's patented esketamine for depression, criticized for being sold without accompanying therapy and thus requiring repeat dosing to sustain revenue).

Doblin walks through the FDA drug-approval pipeline in detail as applied to MAPS's MDMA-for-PTSD program: after early phase-1 protocol rejections in the 1980s-90s, the program reached its end-of-phase-2 meeting with the FDA in November 2016 (30 years after MAPS's founding), having discovered that MDMA-assisted therapy works regardless of PTSD's cause or the patient's sex (unlike existing SSRIs, which work better in women and fail in combat-related PTSD), and that (unlike classic psychedelics) MDMA's therapeutic benefit does not correlate with the depth of "mystical experience." He recounts discovering, contrary to his own graduate dissertation's proposed solution, that no low/moderate MDMA dose could adequately blind a clinical trial without also producing an "anti-therapeutic" discomfort effect — leading FDA and EMA regulators to accept an inactive-placebo-versus-full-dose design instead, relying on random assignment and an independent, rotating pool of blinded raters to control bias. He reports the first phase-3 trial (published in Nature Medicine, 90 chronic severe PTSD patients including prior suicide attempters) achieved extraordinary statistical significance (p=0.0001, versus the standard 0.05 threshold), a very large "placebo-subtracted" effect size (0.91) and within-group effect size (2.1), no site-to-site variation across 15 sites (suggesting the therapy protocol is trainable and replicable, not dependent on a few uniquely gifted therapists), better-than-average outcomes for typically hard-to-treat dissociative-subtype patients, and encouraging durability at longer follow-up — while cautioning that no MDMA-group participants attempted suicide during the trial (versus two placebo-group participants), and that safety, not efficacy, will be the main focus of the still-required second phase-3 trial.

He predicts FDA approval of MDMA for PTSD around the end of 2023 (with psilocybin approval potentially following about a year later), envisions a subsequent decade of proliferating specialized psychedelic clinics, and projects broader "licensed legalization" (allowing supervised personal-growth use with minimal-education requirements, beyond formal medical diagnosis) by around 2035 — modeling this trajectory on how medical marijuana preceded full legalization. He expresses concern that the recent influx of for-profit psychedelic companies could prioritize minimizing therapy time and maximizing drug sales over patient outcomes, but argues MAPS's nonprofit-controlled model and continued drug-policy-reform efforts (creating legal, low-cost personal-use alternatives) can serve as a market-shaping counterexample and check on that dynamic.

On broader civilizational stakes, Doblin frames psychedelics as potentially essential to humanity avoiding self-destruction (citing Einstein's warning that nuclear weapons demand "a new mode of thinking"), hoping widespread, contextually responsible use could foster a sense of universal human connection that reduces tribalism, dehumanization, and dogmatic conflict (envisioning even hostile groups, like police and drug-reform activists, or different religions, being seen as differing "languages" for the same underlying human needs) — offering as one concrete example a police officer, also a trained psychotherapist, currently going through MAPS's MDMA therapist-training program to help fellow officers process occupational trauma. He closes with reflections on meaning and mortality: he doesn't believe humans need definitive answers to questions like "why do we die" or "what is the meaning of life," framing finite life (and even death itself) as what makes life precious rather than tragic, and describes deliberately basing his own sense of accomplishment and happiness on sustained effort rather than outcomes, quoting a family maxim: "we have to make up for the brevity of life with the intensity of life."

Excerpts